Your Value
is our Business.

From the molecule
to the patient.

NUVISAN is your choice.

NUVISAN for

  • BigPharma
  • BioTech
  • Institutions
  • CROs

NUVISAN in

  • Formulation Dev.
  • Chemistry
  • Pharmaceutical
  • Clinical
  • Non-Clinical
  • Analytical

From the molecule
to the patient.

NUVISAN is your choice.

The fully integrated European CRO / CDMO
providing all relevant GxP services.

With more than 40 years of experience in projects
for BigPharma, BioTech, Academic Institutions and CROs.

PRESS RELEASE | NEU-ULM | BERLIN 18.08.2020

We fight COVID-19 together
Our INNOVATION CAMPUS BERLIN is part of the CARE (Corona Accelerated R&D in Europe) team

INNOVATION CAMPUS BERLIN is a proud Partner of Europe’s Largest Initiative to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats which is launched today in cooperation with the European Union, the European Federation of Pharmaceutical Industries, Associations (EFPIA) companies and IMI-Associated Partners.

Read the press release:
↓read complete press release | PDF | 899 KB

Visit the ICB website: ↓www.InnovationCampusBerlin.com

The NUVISAN Concept

Connected services and support along the value chain
from research up to completions of phase II

API Synthesis

GMP
Method development & Validation

Lead Yes / No Go decision

In vitro / in vivo DMPK (Toxicology)

Formulation Development & Manufacturing

FIM Trial Design/ Drug Exposition

GLP / GCP Bioanalysis

A COMPLETE SERVICE PORTFOLIO ENABLES A PROCESS ORIENTED APPROACH

EU-Import & Packaging & Labeling

Post-clinical Service (Marketing Author.)

Medical Device & Reg. Cosmetic

SafetyLab Services

Clinical Conduct

Clinical Study Protocol Writing & CTA

Regulatory Consulting

NUVISAN provides all services from one single source
according from API Synthesis, Formulation Development
to Non-Clinical, Early Clinical, Pharmaceutical
as well as Bioanalytical Lab Services.

NUVISAN is your choice

PRESS RELEASE | NEU-ULM | BERLIN | 11.02.2020

NUVISAN and Bayer create new research unit in Berlin

Neu-Ulm/ Berlin, February 10, 2020 – NUVISAN has agreed with Bayer to integrate large parts of Bayer’s Berlin-based small molecule research unit and complements hereby its services in the field of preclinical research.

↓ read complete Press Release / PDF / 428 KB

 


Why working with NUVISAN?

1

Years of experience

1

Sites across Europe

10+

High educated motivated people

0

Goal

The molecule maker

NUVISAN the molecule maker

NUVISAN Pharma Services is a fully integrated Contract Research Organization and pharmaceutical service provider with an with a 40-years track record of serving clients’ needs in early and clinical development.

NUVISAN started operations as the privately owned contract research institute, LAB in 1979 and has been performing clinical pharmacological and pharmacokinetic studies, ever since.

Our philosophy is to offer all relevant GxP Services from one source to support clients from discovery to the entry in clinical development.

What can we do for you today?